Clinical trials
Substance Use Disorders clinical trials
Below are recruiting substance use disorders clinical trials, each written for real people, not researchers. We’re tracking 419 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07218354RecruitingPhase 3
Medication for reducing alcohol use in veterans
This study tests whether a medication (semaglutide) can help veterans reduce or stop drinking alcohol. It is for veterans who drink heavily and have alcohol use disorder, and who are interested in cutting down.
Long Beach, CaliforniaAges 18–80 - NCT06124846Recruiting
Cannabis break and brain changes in teens
This study looks at what happens in the brain when teens with cannabis use disorder stop using cannabis for 6 weeks. It uses MRI scans to see changes in areas that control habits and decisions.
Minneapolis, MinnesotaAges 15–18 - NCT07559500RecruitingPhase 1
Study of tirzepatide for alcohol use disorder
This trial tests if tirzepatide, a diabetes drug, affects brain chemistry linked to alcohol use. Researchers want to see if it can help people with mild-to-moderate alcohol use disorder who also have tried stimulants.
Bethesda, MarylandAges 21–65 - NCT04135846RecruitingPhase 2
Alpha-blocker medicine to help reduce alcohol drinking
This Phase 2 trial tests whether blocking certain body signals (alpha receptors) with a study medicine can help people with alcohol use disorder cut down or stop drinking. You may be able to join if you meet alcohol-use criteria and can safely take the study drug.
Providence, Rhode IslandAges 18 years+ - NCT05011266RecruitingPhase 2/Phase 3
Buprenorphine plus naltrexone shot to prevent opioid relapse
This trial tests whether a combination of buprenorphine (through your care plan) and a monthly extended-release naltrexone (XR-NTX) shot can help prevent opioid relapse. It may help people who are ready to move toward a naltrexone-based relapse-prevention treatment after detox.
Rockville, MarylandAges 18–65 - NCT05042102RecruitingPhase 2
Donepezil plus brain training for alcohol use disorder
This Phase 2 study tests whether donepezil, along with structured cognitive (brain) training, can improve outcomes for people with alcohol use disorder. It will measure whether this combination helps after recent heavy drinking, while tracking safety over about 13 weeks.
West Haven, ConnecticutAges 18–80 - NCT05495984Recruiting
Brain change study for mothers in opioid treatment
This study looks at whether supportive interventions can affect brain “plasticity,” or how the brain adapts, in mothers who are in treatment for opioid use disorder. If you qualify, you may be asked to take part in assessments and follow-up so researchers can better understand recovery during early motherhood.
New Haven, ConnecticutAges 21–45 - NCT06160232RecruitingPhase 2
Psilocybin therapy for severe alcohol use disorder
This trial tests whether psilocybin, a psychedelic substance, combined with talk therapy can help people with severe alcohol use disorder stop or reduce drinking. Participants will first complete a 4-week inpatient detox program before receiving psilocybin in a supervised setting.
BrusselsAges 21–64 - NCT06323824RecruitingPhase 4
Methadone vs. buprenorphine for opioid use disorder treatment
This study compares two medications, methadone and buprenorphine, to see which helps people stay in treatment for opioid use disorder. You may be eligible if you are starting a new treatment episode.
Oakland, CaliforniaAges 18–99 - NCT06629259RecruitingPhase 2
Guanfacine for Alcohol Use Disorder
This trial tests if guanfacine, a medication that calms certain brain signals, can help people reduce or stop drinking. You may qualify if you have moderate to severe alcohol use disorder and want to quit.
Indianapolis, IndianaAges 18 years+ - NCT06648642Recruiting
MRI-guided brain stimulation for alcohol use disorder
This study tests whether a new type of brain stimulation, guided by MRI and a robot, can help reduce heavy drinking in people with alcohol use disorder. The treatment is non-invasive and aims to improve brain function related to cravings.
San Antonio, TexasAges 18–65 - NCT06160284RecruitingPhase 1
Psilocybin for brain healing in opioid recovery
This study tests whether psilocybin, a psychedelic substance, can help change brain connections in people recovering from opioid use disorder. It involves brain scans and careful medical monitoring to explore new treatment options.
New Haven, ConnecticutAges 25–55 - NCT06796062RecruitingPhase 2
Psilocybin for opioid use disorder
This study tests whether psilocybin can help people who want to stop using opioids and are already in treatment. Eligible participants receive a single dose of psilocybin in a supervised setting and are followed to see if it reduces opioid use.
Albuquerque, New MexicoAges 18–65 - NCT06832007Recruiting
Light therapy for recovery from opioid use disorder
This study tests whether a special light device used at home can improve recovery in people being treated for opioid use disorder. It looks at how light might help with sleep, mood, and overall well-being.
Birmingham, AlabamaAges 18–60 - NCT07071766Recruiting
Support for new mothers on opioid treatment
This study tests ways to improve outcomes for mothers who are receiving medication for opioid use disorder, from late pregnancy through the first year after giving birth.
Little Rock, ArkansasAges 18 years+ - NCT06236100Recruiting
Family substance use prevention with a family advocate
This study tests whether an extra advocate who helps families deal with past hardships makes a substance use prevention program work better. The program is for families with teens aged 7–17 in certain New Jersey communities that have higher rates of difficult childhood experiences and substance use problems.
Tinton Falls, New JerseyAges 7 years+ - NCT04723498Recruiting
Internet use study for children and teens
This study looks at how problematic (hard-to-control) internet use shows up in children and teens. It may help clinicians understand the patterns of use and improve support for young people and families.
Zurich, Canton of ZurichAges 8–18 - NCT06221839Recruiting
Racism, Decision Making, and Substance Use in Teens
This study looks at how experiences of racism and stress affect decision-making and the risk of substance use in adolescents. It involves an interview and possibly an MRI brain scan.
New York, New YorkAges 11–14 - NCT04616781RecruitingPhase 2/Phase 3
Ketone drink study for alcohol use disorder brain function
This study tests whether a ketone-based treatment (a ketone ester) can change brain activity in people with alcohol use disorder who are not currently seeking treatment. You may also have brain scans, so the study is looking for safe MRI eligibility and certain health factors.
Philadelphia, PennsylvaniaAges 21–65 - NCT05613608RecruitingPhase 2/Phase 3
Cannabidiol (CBD) study for alcohol use disorder
This trial tests whether cannabidiol (CBD) can help people cut down or quit drinking alcohol. It enrolls adults diagnosed with alcohol use disorder and wanting to reduce drinking, while checking for safety and other mental health or drug use factors.
Aurora, ColoradoAges 21 years+ - NCT05913752RecruitingPhase 1/Phase 2
Test drug CMND-100 in people with alcohol use disorder
This early study tests the safety and dosing of CMND-100 in first-time participants, including people with alcohol use disorder (AUD) and some healthy volunteers. It may help researchers understand whether the drug is safe, and how it might affect alcohol use in AUD.
New Haven, ConnecticutAges 18–60 - NCT06489899Recruiting
Peer education for substance use and gender fairness in teens
This trial tests a program where young people learn from peers about reducing substance use and promoting gender equity. Participants will join workshop sessions and vocational training to build skills and healthier habits.
Cape Town, Western CapeAges 16–24 - NCT06585709Recruiting
Brain stimulation for opioid use disorder treatment
This trial tests if brain stimulation can help people starting buprenorphine for opioid use disorder. It aims to improve treatment outcomes and support recovery.
Durham, North CarolinaAges 18 years+ - NCT06642181RecruitingPhase 1
Guanfacine and meditation with buprenorphine for opioid use disorder
This study tests if adding a medication called guanfacine and mindfulness meditation to standard buprenorphine treatment helps people with opioid use disorder. It looks at whether this combination can improve treatment outcomes and reduce opioid use.
Newark, New JerseyAges 18–55
Hear when a new Substance Use Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for substance use disorders?
- Yes. Clin2 currently lists 419 recruiting substance use disorders studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a substance use disorders trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a substance use disorders trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.